Company news from the 05/05/06 News Brief

Share this article:
Biovail and AstraZeneca have entered into an agreement in which Biovail’s specialty sales force will promote AstraZeneca’s Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. AstraZeneca will continue to manufacture and supply all quantities of Zoladex, according to a joint statement from the companies. Biovail’s 85-member specialty sales force currently promotes Zovirax Cream and Zovirax Ointment, topical anti-viral treatments for genital herpes and cold sores, to specialists and selected primary-care physicians in the US.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.